Company / SG&A Expense
FATE THERAPEUTICS INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$74.2M
FY2025
5-year range
$23.6M / $84.2M
FY2021-FY2025
Trend
-8.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $8M in FY2016 to $84M in FY2023.
Based on SEC 10-K filings.
$74M in FY2025 with a 5-year CAGR of +36.2%.
Improved from $84M to $74M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +29.8%
- 5-Year CAGR
- +36.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +36.2%, indicating consistent growth.
- In FY2025, sg&a expense decreased 8.9% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $74.2M | -8.9% |
| FY2024 | $81.4M | -3.3% |
| FY2023 | $84.2M | +148.5% |
| FY2022 | $33.9M | +43.4% |
| FY2021 | $23.6M | +49.5% |
| FY2020 | $15.8M | +33.1% |
| FY2019 | $11.9M | +19.8% |
| FY2018 | $9.9M | -4.2% |
| FY2017 | $10.4M | +22.2% |
| FY2016 | $8.5M | +27.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026